SC
IOVA icon

SouthState Corp’s Iovance Biotherapeutics IOVA Stock Holding History

SouthState Corp’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,000
Closed -$8.6K – 1460
2025
Q2 		$8.6K Buy
+5,000
New +$12.4K ﹤0.01% 811

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SouthState Corp's IOVA Position: Q3 2025 in Review

SouthState Corp sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 5,000 shares — an estimated $8.6K sold.

SouthState Corp first reported a position in IOVA in Q2 2025 and held it in 1 quarter. The position peaked at $8.6K in Q2 2025. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • SouthState Corp reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • SouthState Corp sold 5,000 Iovance Biotherapeutics shares in Q3 2025, an estimated $8.6K.
  • SouthState Corp first reported a position in Iovance Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • SouthState Corp's Iovance Biotherapeutics position peaked at $8.6K in Q2 2025.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on SouthState Corp's 13F filing for Q3 2025, filed 5 Nov 2025.